Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly

Clinical Endocrinology

Volumn 77, Issue 1, 2012, Pages 72-78

  Heck, Ansgar ^a,f   Ringstad, Geir ^a   Fougner, Stine L ^a,b,f   Casar Borota, Olivera ^a,c,d,f   Nome, Terje ^a   Ramm Pettersen, Jon ^e   Bollerslev, Jens ^a,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE;

ACROMEGALY; ADENOMA; ADULT; AGE OF ONSET; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 84862018622     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04286.x     Document Type: Article

References (26)

1. Carlsen, S.M., Lund-Johansen, M., Schreiner, T. et al. (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism, 93, 2984-2990.
2. Raappana, A., Koivukangas, J., Ebeling, T. et al. (2010) Incidence of pituitary adenomas in Northern Finland in 1990-2007. Journal of Clinical Endocrinology and Metabolism, 95, 4268-4275.
3. Mao, Z.G., Zhu, Y.H., Tang, H.L. et al. (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. European Journal of Endocrinology, 162, 661-666.
4. Melmed, S., Colao, A., Barkan, A. et al. (2009) Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism, 94, 1509-1517.
5. Bollerslev, J., Fougner, S.L. & Berg, J.P. (2009) New directions in pharmacological treatment of acromegaly. Expert opinion on investigational drugs, 18, 13-22.
6. Carlsen, S.M., Svartberg, J., Schreiner, T. et al. (2011) Six months preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumor volume, and post-operative cure. Clinical Endocrinology, 74, 736-743.
7. Colao, A., Auriemma, R.S., Lombardi, G. et al. (2011) Resistance to somatostatin analogs in acromegaly. Endocrine Reviews, 32, 247-271.
8. Bhayana, S., Booth, G.L., Asa, S.L. et al. (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 6290-6295. (Pubitemid 41606558)
9. Fougner, S.L., Casar-Borota, O., Heck, A. et al. (2011) Adenoma granulation pattern correlates to clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clinical Endocrinology, 76, 96-102.
10. de Herder, W.W., Taal, H.R., Uitterlinden, P. et al. (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. European Journal of Endocrinology, 153, 67-71. (Pubitemid 41030517)
11. Gilbert, J.A., Miell, J.P., Chambers, S.M. et al. (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clinical Endocrinology, 62, 742-747. (Pubitemid 40825946)
12. Boulby, P. & Rugg-Gunn, F. (2004) T2: the Transverse Relaxation Time. In: P. Tofts ed. Quantitative MRI of the Brain. John Wiley & Sons, Chichester, pp. 143-202.
13. Iuchi, T., Saeki, N., Tanaka, M. et al. (1998) MRI prediction of fibrous pituitary adenomas. Acta neurochirurgica, 140, 779-786. (Pubitemid 28419960)
14. Bonneville, J.F., Bonneville, F. & Cattin, F. (2005) Magnetic resonance imaging of pituitary adenomas. European Radiology, 15, 543-548. (Pubitemid 40347894)
15. Erdag, N., Bhorade, R.M., Alberico, R.A. et al. (2001) Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR. American Journal of Roentgenology, 176, 1319-1326. (Pubitemid 32323282)
16. Hagiwara, A., Inoue, Y., Wakasa, K. et al. (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology, 228, 533-538. (Pubitemid 36910098)
17. Puig-Domingo, M., Resmini, E., Gomez-Anson, B. et al. (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. Journal of Clinical Endocrinology and Metabolism, 95, 4973-4978.
18. Fougner, S.L., Borota, O.C., Berg, J.P. et al. (2008) The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clinical Endocrinology, 68, 458-465. (Pubitemid 351257867)
19. Lundin, P. & Pedersen, F. (1992) Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography, 16, 519-528.
20. Obari, A., Sano, T., Ohyama, K. et al. (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology, 19, 82-91.
21. Bakhtiar, Y., Hirano, H., Arita, K. et al. (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. European Journal of Endocrinology, 163, 531-539.
22. Wade, A.N., Baccon, J., Grady, M.S. et al. (2011) Clinically silent somatotroph adenomas are common. European Journal of Endocrinology, 165, 39-44.
23. Colao, A., Cappabianca, P., Caron, P. et al. (2009) Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clinical Endocrinology, 70, 757-768.
24. Halperin, I., Nicolau, J., Casamitjana, R. et al. (2008) A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Hormone and Metabolic Research, 40, 422-426. (Pubitemid 351967135)
25. Colao, A., Attanasio, R., Pivonello, R. et al. (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 91, 85-92. (Pubitemid 43069122)
26. Horvath, E. & Kovacs, K. (2006) Pathology of acromegaly. Neuroendocrinology, 83, 161-165. (Pubitemid 44578868)